Alzheimer's Disease Really Three Distinct Subtypes
the Psychiatry Advisor take:
Alzheimer’s disease is actually made up of three different subtypes, a finding that could help in the development of more targeted research and treatment for the neurocognitive disorder.
Dale Bredesen, PhD, of the University of California, Los Angeles’ Easton Laboratory for Neurodegenerative Disease Research, and colleagues, conducted a two-year study involving metabolic testing of 50 people.
The subtypes they identified are: inflammatory, in which markers such as C-reactive protein and serum albumin to globulin ratios are increased; non-inflammatory, in which other metabolic abnormalities are present; and cortical, which primarily affects younger people, does not cause memory loss at first, but individuals tend to lose language skills.
In a paper released last year, Bredesen showed that making lifestyle, exercise and diet changes to improve the body's metabolism reversed cognitive decline in nine out of 10 patients with early Alzheimer's disease .
“The important implications of [these findings] are that the optimal treatment may be different for each group, there may be different causes, and, for future clinical trials, it may be helpful to study specific groups separately,” Bredesen said in a statement.
The next step for the researchers is to figure out whether the subtypes have different underlying causes, and if they respond differently to potential treatments.
The finding could help in the development of more targeted research and treatments for the neurocognitive disorder.
Alzheimer's disease, long thought to be a single disease, really consists of three distinct subtypes, according to a UCLA study.
The finding could lead to more highly targeted research and, eventually, new treatments for the debilitating neurological disorder, which robs people of their memories.
The study further found that one of the three variations, the cortical subtype, appears to be fundamentally a different condition than the other two, said Dr. Dale Bredesen, the study's author, a UCLA professor of neurology and member of the Easton Laboratory for Neurodegenerative Disease Research.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- Functional Restoration for Chronic Pain and Depression in the Elderly: Pharmacotherapy and Beyond
- Efficacy of Long-Acting Injectable Antipsychotics vs Oral Antipsychotics
- Older Age Associated With Worse Major Depressive Disorder Outcomes
- Preoperative Psychiatric Diagnoses Not Associated With Bariatric Surgery Outcomes
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations